The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03.
AIMS: Since its launch in the prescribing market in 1999 for the treatment of opiate dependence, buprenorphine has rapidly become established as an alternative to methadone treatment in the United Kingdom. In the absence of evidence of its clinical superiority over methadone, and given its high rela...
| Publicado en: | Addiction Vol. 100; no. 4; pp. 495 - 500 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Apr2005
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106644305&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106644305 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09652140 AIO jtl: Addiction issn: 09652140 maglogo: Y pubinfo: dt: Apr2005 vid: 100 iid: 4 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 106644305 106644305 2005092065 10.1111/j.1360-0443.2005.01039.x NLM15784064 106644305 ppf: 495 ppct: 5 formats: fmt: @attributes: type: P tig: atl: The rise of buprenorphine prescribing in England: analysis of NHS regional data, 2001-03. aug: au: de Wet CJ Reed LJ Bearn J affil: Wickham Park House, South London and Maudsley NHS Trust, Bethlem Royal Hospital, Beckenham, Kent sug: subj: Buprenorphine Therapeutic Use Substance Dependence Drug Therapy Costs and Cost Analysis England Methadone Therapeutic Use National Health Programs Pharmacy, Retail Human ab: AIMS: Since its launch in the prescribing market in 1999 for the treatment of opiate dependence, buprenorphine has rapidly become established as an alternative to methadone treatment in the United Kingdom. In the absence of evidence of its clinical superiority over methadone, and given its high relative cost, we sought to examine the impact of buprenorphine availability on opiate treatment services in England. METHODS: Quarterly buprenorphine and methadone community prescription figures were obtained for 28 Strategic Health Authorities (SHAs) in England, for the 2-year period September 2001 to September 2003. Rates of buprenorphine prescribing (as proportion of all opiate prescriptions) were examined over time by number of prescriptions and net ingredient cost. RESULTS: Buprenorphine prescription rates increased disproportionately to methadone in all 28 SHAs. By the end of 2003 the number of buprenorphine prescriptions had increased to 23% of all opiate prescriptions, but accounted for 45% of opiate prescription costs in England. Buprenorphine prescribing rates varied substantially across different regions. CONCLUSIONS: Buprenorphine prescribing has increased dramatically and represents a disproportionately large fraction of community opiate prescribing costs. The marked regional variation suggests the need for further research and the development of national guidelines to support rational prescribing and equitable access to treatment. pubtype: Academic Journal doctype: research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|